This page contains a Flash digital edition of a book.
18 DRUG DISCOVERY AND DEVELOPMENT


Fig. 1. Bayer Pharma will use Chromobody technology for real-time monitoring of cell cycle progression in drug discovery.


Development and licensing deals speed up new drug development


Technology licensing tie-ups and more targeted discovery solutions are driving new drug developments.


Les alliances dans le domaine des licences technologiques et les solutions pour découvertes plus ciblées donnent un essor au développement de nouveaux médicaments.


Technologielizenzkooperationen und gezieltere Erkennungslösungen kurbeln neue Medikamentenentwicklungen an.


B


iopharmaceutical company Receptos has announced the establishment of a


development license and option agreement with AbbVie — established from Abbott’s separated research pharmaceuticals business on 1 January — to in-license a humanised anti-interleukin-13 (IL-13) antibody asset, designated RPC4046 by Receptos.


Under the agreement, Receptos will conduct a Phase II clinical study seeking to demonstrate proof of concept in eosinophilic esophagitis, a chronic, allergic/immune-mediated disease that typically displays symptoms related to esophageal dysfunction and eosinophil-


www.scientistlive.com


predominant inflammation. Te indication has been designated as an orphan disease by the US Food and Drug Administration (FDA).


For its part, AbbVie has an exclusive option to begin a global co-development collaboration with Receptos for the compound following the results of the study and regulatory discussions with the FDA.


Should AbbVie exercise its option, the two companies would establish a collaboration agreement in which they would equally share the costs of a Phase III clinical programme as well as future development on a global basis.


Currently there are no FDA- approved drugs for treating eosinophilic esophagitis. Existing options see patients treated with topical steroids. However, most relapse within four months. Recent estimates for the eosinophilic esophagitis patient population in 2012, based on diagnosis and


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52